样式: 排序: IF: - GO 导出 标记为已读
-
Modularization of adhesion G protein-coupled receptor (aGPCR) structure: how alternative splicing regulates synaptogenesis Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-24 Tobias Langenhan
-
Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-24 Jinyuan Wang, Jinlu Zhang, Shicheng Yu, Hongyan Li, Shaohong Chen, Jingting Luo, Haibo Wang, Yuxia Guan, Haihan Zhang, Shiyi Yin, Huili Wang, Heping Li, Junle Liu, Jingyuan Zhu, Qiong Yang, Ying Sha, Chuan Zhang, Yuhang Yang, Xuan Yang, Xifang Zhang, Xiuli Zhao, Likun Wang, Liping Yang, Wenbin Wei
-
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-24 Hui Qian, Chen-Hong Ding, Fang Liu, Shi-Jie Chen, Chen-Kai Huang, Meng-Chao Xiao, Xia-Lu Hong, Ming-Chen Wang, Fang-Zhi Yan, Kai Ding, Ya-Lu Cui, Bai-Nan Zheng, Jin Ding, Cheng Luo, Xin Zhang, Wei-Fen Xie
-
FGF7 enhances the expression of ACE2 in human islet organoids aggravating SARS-CoV-2 infection Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-23 Hao Meng, Zhiying Liao, Yanting Ji, Dong Wang, Yang Han, Chaolin Huang, Xujuan Hu, Jingyi Chen, Hengrui Zhang, Zonghong Li, Changliang Wang, Hui Sun, Jiaqi Sun, Lihua Chen, Jiaxiang Yin, Jincun Zhao, Tao Xu, Huisheng Liu
-
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-23 Yunfei Chen, Yanmei Xu, Ying Chi, Ting Sun, Yuchen Gao, Xueqing Dou, Zhibo Han, Feng Xue, Huiyuan Li, Wei Liu, Xiaofan Liu, Huan Dong, Rongfeng Fu, Mankai Ju, Xinyue Dai, Wentian Wang, Yueshen Ma, Zhen Song, Jundong Gu, Wei Gong, Renchi Yang, Lei Zhang
-
PBX/Knotted 1 homeobox-2 (PKNOX2) is a novel regulator of myocardial fibrosis Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-22 Liang Chen, Haotong Li, Xiaorui Liu, Ningning Zhang, Kui Wang, Anteng Shi, Hang Gao, Deniz Akdis, Ardan M. Saguner, Xinjie Xu, Elena Osto, Willem Van de Veen, Guangyu Li, Antoni Bayés-Genís, Firat Duru, Jiangping Song, Xiangjie Li, Shengshou Hu
-
A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-20 Wei Zhu, Zhiming Zhang, Jinzhang Chen, Xiaolan Chen, Lei Huang, Xiaoyong Zhang, Xuan Huang, Na Ma, Weikang Xu, Xuan Yi, Xinyu Lu, Xin Fu, Siwei Li, Guoheng Mo, Yiyue Wang, Guosheng Yuan, Mengya Zang, Qi Li, Xiaotao Jiang, Yajing He, Sha Wu, Yukai He, Yongyin Li, Jinlin Hou
-
The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-19 Bo Cheng, Caichen Li, Jianfu Li, Longlong Gong, Peng Liang, Ying Chen, Shuting Zhan, Shan Xiong, Ran Zhong, Hengrui Liang, Yi Feng, Runchen Wang, Haixuan Wang, Hongbo Zheng, Jun Liu, Chengzhi Zhou, Wenlong Shao, Yuan Qiu, Jiancong Sun, Zhanhong Xie, Zhu Liang, Chenglin Yang, Xiuyu Cai, Chunxia Su, Wei Wang, Jianxing He, Wenhua Liang
-
Drug repurposing for cancer therapy Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-19 Ying Xia, Ming Sun, Hai Huang, Wei-Lin Jin
-
METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-17 Yue-fan Wang, Wen-li Zhang, Zhi-xuan Li, Yue Liu, Jian Tan, Hao-zan Yin, Zhi-chao Zhang, Xian-jie Piao, Min-hao Ruan, Zhi-hui Dai, Si-jie Wang, Chen-yang Mu, Ji-hang Yuan, Shu-han Sun, Hui Liu, Fu Yang
-
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-17 Huaqing Wang, Jifeng Feng, Yanyan Liu, Zhengzi Qian, Da Gao, Xuehong Ran, Hui Zhou, Lihong Liu, Binghua Wang, Meiyun Fang, Hebing Zhou, Zhenqian Huang, Shi Tao, Zhuowen Chen, Liping Su, Hang Su, Yu Yang, Xiaobao Xie, Huijing Wu, Ping Sun, Guoyu Hu, Aibin Liang, Zhiming Li
-
Pandemic punch: SARS-CoV-2 hits pancreas Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-16 Ninel Azoitei, Sandra Heller, Alexander Kleger
-
Poly(A)-specific RNase (PARN) generates and regulates miR-125a-5p 3’-isoforms, displaying an altered expression in breast cancer Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-15 Luisa Tomasello, Shoshanah M. Holub, Giovanni Nigita, Rosario Distefano, Carlo M. Croce
-
Anti-lymphangiogenesis for boosting drug accumulation in tumors Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-15 Chunling Wang, Junchao Xu, Xiaoyu Cheng, Ge Sun, Fenfen Li, Guangjun Nie, Yinlong Zhang
-
Infection with SARS-CoV-2 can cause pancreatic impairment Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-12 Wei Deng, Linlin Bao, Zhiqi Song, Ling Zhang, Pin Yu, Yanfeng Xu, Jue Wang, Wenjie Zhao, Xiuqin Zhang, Yunlin Han, Yanhong Li, Jiangning Liu, Qi Lv, Xujian Liang, Fengdi Li, Feifei Qi, Ran Deng, Siyuan Wang, Yibai Xiong, Ruiping Xiao, Hongyang Wang, Chuan Qin
-
G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-10 Mingyang Zhang, Ting Chen, Xun Lu, Xiaobing Lan, Ziqiang Chen, Shaoyong Lu
-
The gasdermin family: emerging therapeutic targets in diseases Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-08 Chenglong Zhu, Sheng Xu, Ruoyu Jiang, Yizhi Yu, Jinjun Bian, Zui Zou
-
Thiamine-modified metabolic reprogramming of human pluripotent stem cell-derived cardiomyocyte under space microgravity Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-08 Xinglong Han, Lina Qu, Miao Yu, Lingqun Ye, Liujia Shi, Guangfu Ye, Jingsi Yang, Yaning Wang, Hao Fan, Yong Wang, Yingjun Tan, Chunyan Wang, Qi Li, Wei Lei, Jianghai Chen, Zhaoxia Liu, Zhenya Shen, Yinghui Li, Shijun Hu
-
Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-05 Chuan Yang, Xueping Wang, Kenneth K. W. To, Caimei Cui, Min Luo, Shaocong Wu, Lamei Huang, Kai Fu, Can Pan, Zeyu Liu, Teng Fan, Caibo Yang, Fang Wang, Liwu Fu
Circulating tumor cells (CTCs) are precursors of distant metastasis in a subset of cancer patients. A better understanding of CTCs heterogeneity and how these CTCs survive during hematogenous dissemination could lay the foundation for therapeutic prevention of cancer metastasis. It remains elusive how CTCs evade immune surveillance and elimination by immune cells. In this study, we unequivocally identified
-
Protein neddylation and its role in health and diseases Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-05 Shizhen Zhang, Qing Yu, Zhijian Li, Yongchao Zhao, Yi Sun
NEDD8 (Neural precursor cell expressed developmentally downregulated protein 8) is an ubiquitin-like protein that is covalently attached to a lysine residue of a protein substrate through a process known as neddylation, catalyzed by the enzyme cascade, namely NEDD8 activating enzyme (E1), NEDD8 conjugating enzyme (E2), and NEDD8 ligase (E3). The substrates of neddylation are categorized into cullins
-
Adeno-associated virus as a delivery vector for gene therapy of human diseases Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-03 Jiang-Hui Wang, Dominic J. Gessler, Wei Zhan, Thomas L. Gallagher, Guangping Gao
Adeno-associated virus (AAV) has emerged as a pivotal delivery tool in clinical gene therapy owing to its minimal pathogenicity and ability to establish long-term gene expression in different tissues. Recombinant AAV (rAAV) has been engineered for enhanced specificity and developed as a tool for treating various diseases. However, as rAAV is being more widely used as a therapy, the increased demand
-
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-03 Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan Xia
Fluoropyrimidine-based combination chemotherapy plus targeted therapy is the standard initial treatment for unresectable metastatic colorectal cancer (mCRC), but the prognosis remains poor. This phase 3 trial (ClinicalTrials.gov: NCT03950154) assessed the efficacy and adverse events (AEs) of the combination of PD-1 blockade-activated DC-CIK (PD1-T) cells with XELOX plus bevacizumab as a first-line
-
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-03 Jing Wang, Baizhou Li, Meng Luo, Jia Huang, Kun Zhang, Shu Zheng, Suzhan Zhang, Jiaojiao Zhou
Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in distinguishing between non-progressive and progressive DCIS, often resulting in over- or under-treatment in many cases. With increasing screen-detected DCIS in these years, the nature of DCIS has aroused worldwide attention. A deeper
-
Macrocyclic peptides: up-and-coming weapons to combat antimicrobial resistance Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-02 Wen-Jing Wang, Xiang-Min Dong, Guo-Bo Li
-
Neutrophils are shaped by the tumor microenvironment: novel possibilities for targeting neutrophils in cancer Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-02 Carlos Silvestre-Roig, Lydia Kalafati, Triantafyllos Chavakis
-
Optimizing oncolytic virus design: a “Swiss army knife” approach to create a systemically delivered therapeutic Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-02 Carolina S. Ilkow, John Cameron Bell
-
Mex-3 RNA binding family member A (MEX3A)/circMPP6 complex promotes colorectal cancer progression by inhibiting autophagy Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-02 Ri-Xin Chen, Shui-Dan Xu, Min-Hua Deng, Shi-Hui Hao, Jie-Wei Chen, Xiao-Dan Ma, Wei-Tao Zhuang, Jing-Hua Cao, Yong-Rui Lv, Jin-Long Lin, Si-Yu Li, Gui-Bin Qiao, Dan Xie, Feng-Wei Wang
RNA-binding proteins (RBPs)-RNA networks have contributed to cancer development. Circular RNAs (circRNAs) are considered as protein recruiters; nevertheless, the patterns of circRNA-protein interactions in colorectal cancer (CRC) are still lacking. Processing bodies (PBs) formed through liquid-liquid phase separation (LLPS) are membrane-less organelles (MLOs) consisting of RBPs and RNA. Previous evidence
-
Messing with cancer therapy: how the melanoma phenotype predicts checkpoint inhibitor response Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-01 Svenja Meierjohann, Corine Bertolotto
-
The two sides of chromosomal instability: drivers and brakes in cancer Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-29 Rendy Hosea, Sharon Hillary, Sumera Naqvi, Shourong Wu, Vivi Kasim
-
Rapid development of double-hit mRNA antibody cocktail against orthopoxviruses Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-27 Hang Chi, Suo-Qun Zhao, Ru-Yi Chen, Xing-Xing Suo, Rong-Rong Zhang, Wen-Hui Yang, Dong-Sheng Zhou, Min Fang, Bo Ying, Yong-Qiang Deng, Cheng-Feng Qin
-
RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-27 Wei-Wei Liu, Si-Qing Zheng, Tian Li, Yun-Fei Fei, Chen Wang, Shuang Zhang, Fei Wang, Guan-Min Jiang, Hao Wang
-
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-25 Xiaofeng Chen, Hao Xu, Xiaobing Chen, Tongpeng Xu, Yitong Tian, Deqiang Wang, Fen Guo, Kangxin Wang, Guangfu Jin, Xiao Li, Rong Wang, Fengyuan Li, Yongbin Ding, Jie Tang, Yueyu Fang, Jing Zhao, Liang Liu, Ling Ma, Lijuan Meng, Zhiguo Hou, Rongrong Zheng, Yang Liu, Ni Guan, Bei Zhang, Shuang Tong, Shiqing Chen, Xing Li, Yongqian Shu
-
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-25 Jian-Bang Xu, Wei-Jie Guan, Yi-Lin Zhang, Zhuo-Er Qiu, Lei Chen, Xiao-Chun Hou, Junqing Yue, Yu-Yun Zhou, Jie Sheng, Lei Zhao, Yun-Xin Zhu, Jing Sun, Jincun Zhao, Wen-Liang Zhou, Nan-Shan Zhong
-
Harnessing innate immune pathways for therapeutic advancement in cancer Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-25 Ankang Hu, Li Sun, Hao Lin, Yuheng Liao, Hui Yang, Ying Mao
-
TGF-β signaling in health, disease, and therapeutics Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-22 Ziqin Deng, Tao Fan, Chu Xiao, He Tian, Yujia Zheng, Chunxiang Li, Jie He
-
Cholesterol business: life or death by rust Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-21 Shubhangi Gavali, Francesca Maremonti, Andreas Linkermann
-
Protein lipidation in health and disease: molecular basis, physiological function and pathological implication Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-15 Yuan Yuan, Peiyuan Li, Jianghui Li, Qiu Zhao, Ying Chang, Xingxing He
-
Diabetes and pulmonary infection: how hyperglycaemia shapes the immune system Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-13 Christian Herder, Michael Roden, Nicolas Venteclef
-
Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-12 Zhenzhen Fang, Gang Shen, Yina Wang, Fuyan Hong, Xiumei Tang, Yongcheng Zeng, Ting Zhang, Huanyi Liu, Yanmei Li, Jinhong Wang, Jing Zhang, Anton Gao, Weiwei Qi, Xia Yang, Ti Zhou, Guoquan Gao
-
Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-11 Yu-Ling Xiao, Yue Gong, Ying-Jia Qi, Zhi-Ming Shao, Yi-Zhou Jiang
-
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-11 Zhengyang Yang, Jiale Gao, Jianyong Zheng, Jiagang Han, Ang Li, Gang Liu, Yi Sun, Jie Zhang, Guangyong Chen, Rui Xu, Xiao Zhang, Yishan Liu, Zhigang Bai, Wei Deng, Wei He, Hongwei Yao, Zhongtao Zhang
-
Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-09 Jian Zhang, Kejia Zhao, Wenjing Zhou, Ran Kang, Shiyou Wei, Yueli Shu, Cheng Yu, Yin Ku, Yonghong Mao, Hao Luo, Juqin Yang, Jiandong Mei, Qiang Pu, Senyi Deng, Zhengyu Zha, Gang Yuan, Shensi Shen, Yaohui Chen, Lunxu Liu
-
Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-08 Qian Zhou, Yu Meng, Daishi Li, Lei Yao, Jiayuan Le, Yihuang Liu, Yuming Sun, Furong Zeng, Xiang Chen, Guangtong Deng
-
Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-08 Yan Fu, Keyu Shen, Hao Wang, Shun Wang, Xufeng Wang, Le Zhu, Yan Zheng, Tiantian Zou, Hongfei Ci, Qiongzhu Dong, Lun-Xiu Qin
-
Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-07 Lei Ma, Chong Chen, Chunxing Zhao, Tong Li, Lingyu Ma, Jiayu Jiang, Zhaojun Duan, Qin Si, Tsung-Hsien Chuang, Rong Xiang, Yunping Luo
-
Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-06 Jie Xiong, Shu Cheng, Xiao Gao, Shan-He Yu, Yu-Ting Dai, Xin-Yun Huang, Hui-Juan Zhong, Chao-Fu Wang, Hong-Mei Yi, Hao Zhang, Wei-Guo Cao, Rong Li, Wei Tang, Yan Zhao, Peng-Peng Xu, Li Wang, Wei-Li Zhao
-
Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1 Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-06 Xiong Xie, Qiaoshuai Lan, Jinyi Zhao, Sulin Zhang, Lu Liu, Yumin Zhang, Wei Xu, Maolin Shao, Jingjing Peng, Shuai Xia, Yan Zhu, Keke Zhang, Xianglei Zhang, Ruxue Zhang, Jian Li, Wenhao Dai, Zhen Ge, Shulei Hu, Changyue Yu, Jiang Wang, Dakota Ma, Mingyue Zheng, Haitao Yang, Gengfu Xiao, Zihe Rao, Lu Lu, Leike Zhang, Fang Bai, Yao Zhao, Shibo Jiang, Hong Liu
-
NF-κB in biology and targeted therapy: new insights and translational implications Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-04 Qing Guo, Yizi Jin, Xinyu Chen, Xiaomin Ye, Xin Shen, Mingxi Lin, Cheng Zeng, Teng Zhou, Jian Zhang
-
New clinical trial design in precision medicine: discovery, development and direction Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-04 Xiao-Peng Duan, Bao-Dong Qin, Xiao-Dong Jiao, Ke Liu, Zhan Wang, Yuan-Sheng Zang
-
Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-04 Yuanliang Yan, Shangjun Zhou, Xi Chen, Qiaoli Yi, Songshan Feng, Zijin Zhao, Yuanhong Liu, Qiuju Liang, Zhijie Xu, Zhi Li, Lunquan Sun
-
Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-01 Lu Qian, Yanli Zhu, Chao Deng, Zhenxing Liang, Junmin Chen, Ying Chen, Xue Wang, Yanqing Liu, Ye Tian, Yang Yang
-
Contactin-associated protein-like 2 (CNTNAP2) mutations impair the essential α-secretase cleavages, leading to autism-like phenotypes Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-03-01 Qing Zhang, Mengen Xing, Zhengkai Bao, Lu Xu, Yang Bai, Wanqi Chen, Wenhao Pan, Fang Cai, Qunxian Wang, Shipeng Guo, Jing Zhang, Zhe Wang, Yili Wu, Yun Zhang, Jia-Da Li, Weihong Song
-
Eosinophils promote CD8+ T cell memory generation to potentiate anti-bacterial immunity Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-02-28 Jun Zhou, Jiaqi Liu, Bingjing Wang, Nan Li, Juan Liu, Yanmei Han, Xuetao Cao
-
Eliciting CD4-mimicking broadly neutralizing antibodies: new avenues towards the rational design of an HIV vaccine Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-02-29 Frauke Muecksch, Oliver T. Fackler
-
Navigating Epstein–Barr virus autoimmunity: role of NK cells and T cells in multiple sclerosis Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-02-29 Chu Xie, Cong Sun, Mu-Sheng Zeng
-
Resilience conferred by APOE-R136S: a defense bestowed by nature to combat Alzheimer’s disease Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-02-29 Bin Xiao, Joshua Kuruvilla, Eng-King Tan
-
Metabolic memory: mechanisms and diseases Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-02-28 Hao Dong, Yuezhang Sun, Lulingxiao Nie, Aimin Cui, Pengfei Zhao, Wai Keung Leung, Qi Wang
-
Precise genome-editing in human diseases: mechanisms, strategies and applications Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-02-26 Yanjiang Zheng, Yifei Li, Kaiyu Zhou, Tiange Li, Nathan J. VanDusen, Yimin Hua
-
Feeding the vasculature with cruciferous vegetables: a secret for organ protection Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-02-23 Priya Veluswamy, Jens Wippermann, Max Wacker
-
Protein translation: biological processes and therapeutic strategies for human diseases Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-02-23 Xuechao Jia, Xinyu He, Chuntian Huang, Jian Li, Zigang Dong, Kangdong Liu